ABDX - Ticker AI Digest

Abingdon Health Plc 📰 2
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Abingdon Health Plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
ABDX Data 2026-01-15 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (ABDX) 2
ABDX 06:02
Abingdon Health Plc
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health PLC, a leading med-tech contract service provider, released a trading update on January 15, 2026, highlighting significant growth and a positive outlook. Key points include
1. **Revenue Growth**H1 FY26 revenues increased by 45% to £4.5 million, driven by major commercial contracts secured over the past year.
2. **Cash Position**Cash and cash equivalents rose to £3.6 million at December 31, 2025, following a £3.2 million fundraise in October 2025 to support U.S. expansion and working capital needs.
3. **Outlook**The Board remains confident in the commercial outlook, maintaining FY26 revenue guidance of £12.6 million. Revenue is expected to be weighted towards H2 FY26, with anticipated profitability and positive operating cash flow.
4. **Contract Adjustments**Revenue from customer Find Out From Home (FOFH) is now expected in FY27 due to FOFH’s fundraising process, but this does not impact overall FY26 revenue expectations.
5. **U.S. Expansion**The Company is accelerating its lateral flow development and manufacturing capabilities in Madison, WI, to meet customer demand.
6. **Investor Presentation**Executive Chairman Dr. Chris Hand presented at the Proactive One2One Investor Forum on January 15, 2026, emphasizing the Company’s integrated CDMO and CRO service offerings and momentum in securing major contracts.
Abingdon Health continues to focus on its end-to-end services, regulatory support, and international expansion, positioning itself for sustained growth in the med-tech sector.
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text. Since the text does not explicitly mention debt figures, the table focuses on revenue and cash equivalents.
MetricH1 FY25H1 FY26Change
Total Revenues (£ million)3.14.5+45%
Cash and Cash Equivalents (£ million)1.93.6+89%
Debt InformationNot provided in the text
### Explanation: 1. **Total Revenues**: H1 FY25 was £3.1 million, and H1 FY26 increased to £4.5 million, representing a 45% growth. 2. **Cash and Cash Equivalents**: Increased from £1.9 million in June 2025 to £3.6 million in December 2025, an 89% rise. 3. **Debt Information**: The text does not provide details on debt, so the table notes this as "Not provided." This table is responsive and can be easily styled further with CSS.
ABDX 06:01
Abingdon Health Plc
Appointment of NOMAD & Corporate Broker
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 1
ABDX 06:01
Abingdon Health Plc
European patent for AppDx® smartphone reader
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s and med-tech solutions, announced on December 18, 2025, the granting of a European patent (EP4150565) for its AppDx® lateral flow smartphone reader. This patent, titled "Assay Reading Method," complements existing patents in the USA and UK. AppDx® is a software development kit that enables the reading of colorimetric lateral-flow tests using smartphone cameras, providing qualitative and semi-quantitative results. The technology leverages image processing and deep learning algorithms tailored for each test. Dr. Chris Hand, Executive Chairman, highlighted the patent as a testament to Abingdon Healths innovation and its value to contract development and manufacturing customers. The company, founded in 2008 and headquartered in York, UK, specializes in lateral flow product development, regulatory support, and manufacturing services, with additional regulatory and analytical testing subsidiaries. This announcement was distributed via Reach, the non-regulatory press release service of the London Stock Exchange.
Patents
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
ABDX 06:02
Abingdon Health Plc
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health PLC, a leading med-tech contract service provider, released a trading update on January 15, 2026, highlighting significant growth and a positive outlook. Key points include
1. **Revenue Growth**H1 FY26 revenues increased by 45% to £4.5 million, driven by major commercial contracts secured over the past year.
2. **Cash Position**Cash and cash equivalents rose to £3.6 million at December 31, 2025, following a £3.2 million fundraise in October 2025 to support U.S. expansion and working capital needs.
3. **Outlook**The Board remains confident in the commercial outlook, maintaining FY26 revenue guidance of £12.6 million. Revenue is expected to be weighted towards H2 FY26, with anticipated profitability and positive operating cash flow.
4. **Contract Adjustments**Revenue from customer Find Out From Home (FOFH) is now expected in FY27 due to FOFH’s fundraising process, but this does not impact overall FY26 revenue expectations.
5. **U.S. Expansion**The Company is accelerating its lateral flow development and manufacturing capabilities in Madison, WI, to meet customer demand.
6. **Investor Presentation**Executive Chairman Dr. Chris Hand presented at the Proactive One2One Investor Forum on January 15, 2026, emphasizing the Company’s integrated CDMO and CRO service offerings and momentum in securing major contracts.
Abingdon Health continues to focus on its end-to-end services, regulatory support, and international expansion, positioning itself for sustained growth in the med-tech sector.
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text. Since the text does not explicitly mention debt figures, the table focuses on revenue and cash equivalents.
MetricH1 FY25H1 FY26Change
Total Revenues (£ million)3.14.5+45%
Cash and Cash Equivalents (£ million)1.93.6+89%
Debt InformationNot provided in the text
### Explanation: 1. **Total Revenues**: H1 FY25 was £3.1 million, and H1 FY26 increased to £4.5 million, representing a 45% growth. 2. **Cash and Cash Equivalents**: Increased from £1.9 million in June 2025 to £3.6 million in December 2025, an 89% rise. 3. **Debt Information**: The text does not provide details on debt, so the table notes this as "Not provided." This table is responsive and can be easily styled further with CSS.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 4
ABDX 06:02
Abingdon Health Plc
Trading Update
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health PLC, a leading med-tech contract service provider, released a trading update on January 15, 2026, highlighting significant growth and a positive outlook. Key points include
1. **Revenue Growth**H1 FY26 revenues increased by 45% to £4.5 million, driven by major commercial contracts secured over the past year.
2. **Cash Position**Cash and cash equivalents rose to £3.6 million at December 31, 2025, following a £3.2 million fundraise in October 2025 to support U.S. expansion and working capital needs.
3. **Outlook**The Board remains confident in the commercial outlook, maintaining FY26 revenue guidance of £12.6 million. Revenue is expected to be weighted towards H2 FY26, with anticipated profitability and positive operating cash flow.
4. **Contract Adjustments**Revenue from customer Find Out From Home (FOFH) is now expected in FY27 due to FOFH’s fundraising process, but this does not impact overall FY26 revenue expectations.
5. **U.S. Expansion**The Company is accelerating its lateral flow development and manufacturing capabilities in Madison, WI, to meet customer demand.
6. **Investor Presentation**Executive Chairman Dr. Chris Hand presented at the Proactive One2One Investor Forum on January 15, 2026, emphasizing the Company’s integrated CDMO and CRO service offerings and momentum in securing major contracts.
Abingdon Health continues to focus on its end-to-end services, regulatory support, and international expansion, positioning itself for sustained growth in the med-tech sector.
Below is the HTML table code comparing the financials and debt year-on-year based on the provided text. Since the text does not explicitly mention debt figures, the table focuses on revenue and cash equivalents.
MetricH1 FY25H1 FY26Change
Total Revenues (£ million)3.14.5+45%
Cash and Cash Equivalents (£ million)1.93.6+89%
Debt InformationNot provided in the text
### Explanation: 1. **Total Revenues**: H1 FY25 was £3.1 million, and H1 FY26 increased to £4.5 million, representing a 45% growth. 2. **Cash and Cash Equivalents**: Increased from £1.9 million in June 2025 to £3.6 million in December 2025, an 89% rise. 3. **Debt Information**: The text does not provide details on debt, so the table notes this as "Not provided." This table is responsive and can be easily styled further with CSS.
ABDX 06:01
Abingdon Health Plc
Appointment of NOMAD & Corporate Broker
ABDX 13:36
Abingdon Health Plc
Exercise of options and total voting rights
ABDX 06:01
Abingdon Health Plc
European patent for AppDx® smartphone reader
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s and med-tech solutions, announced on December 18, 2025, the granting of a European patent (EP4150565) for its AppDx® lateral flow smartphone reader. This patent, titled "Assay Reading Method," complements existing patents in the USA and UK. AppDx® is a software development kit that enables the reading of colorimetric lateral-flow tests using smartphone cameras, providing qualitative and semi-quantitative results. The technology leverages image processing and deep learning algorithms tailored for each test. Dr. Chris Hand, Executive Chairman, highlighted the patent as a testament to Abingdon Healths innovation and its value to contract development and manufacturing customers. The company, founded in 2008 and headquartered in York, UK, specializes in lateral flow product development, regulatory support, and manufacturing services, with additional regulatory and analytical testing subsidiaries. This announcement was distributed via Reach, the non-regulatory press release service of the London Stock Exchange.
Patents

Today's AI

Today's AI Starts With News

2 live catalysts is opening Today’s AI for ABDX.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-01-15 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
2 Today
Front Of Desk
Abingdon Health Plc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
06:01 Today's Catalyst Appointment of NOMAD & Corporate Broker
Single-Ticker Today's AI
ABDX signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Abingdon Health Plc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for ABDX on 2026-01-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
30.1M
Enterprise Value
4.2M
Public Float
66.8
Broker Target
19
Shares Out
251.1M
Long Interest
0
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

2 live alerts now opens the financials desk for ABDX.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-01-15 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
2 Alerts
Front Of Desk
Abingdon Health Plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
06:01 Today's Alert Appointment of NOMAD & Corporate Broker
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890.0K
Cash
1.9M
EPS
-0.01
Net Income
-3.4M
Revenue
8.4M
Enterprise Value
4.2M
Trailing PE
-
Forward PE
80
Price Sales TTM
3.0886
Price Book MRQ
4.7817
EV Revenue
2.8594
EV EBITDA
-0.2499
Financial Forecastist

Improving financial engine

Revenue is accelerating +75.8% against the prior comparable period. Net margin is compressing by 5.4 pts. Net debt is building +178.7%.

Revenue +75.8% Net Income +94.9% FCF +7.5% Current Ratio 1.91x Forward Rev 0
Improving
Quarter Revenue
4.2M
+75.8%
vs prior comparable quarter
Net Margin
-55.4%
-5.4 pts
profitability pulse
Free Cash Flow
-1.3M
+7.5%
cash conversion
Net Debt / EBITDA
1.1x
+178.7%
lower is cleaner
Revenue Engine

Latest quarter printed 4.2M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -2.3M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 3.7M while net debt is -2.8M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q4 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q4 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
12.2M
Revenue Path
-0.00
EPS / Earnings
Growth cue +0.9%
FY 2027
Consensus
15.2M
Revenue Path
0.00
EPS / Earnings
Growth cue +1.6%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 4.2M -2.3M -1.3M -2.8M
Q2 2025 5.3M -894.0K -1.3M -890.0K
Q4 2024 3.1M -2.5M -2.2M -2.7M
Q2 2024 3.7M -66.0K -477.0K -391.0K
Q4 2023 2.4M -1.2M -1.2M -990.0K
Q2 2023 2.9M -1.0M -1.1M -2.2M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 8.4M -3.4M -3.1M -3.4M
FY 2024 6.1M -1.3M -916.0K -1.7M
FY 2023 4.0M -3.5M -2.8M 845.0K
FY 2022 2.8M -21.3M -20.0M -8.5M
FY 2021 11.6M -7.0M -6.1M -20.1M

Structure DNA

Market Structure DNA has not been loaded for this ticker yet. Once the A15 loader runs, this desk will light up with regime labels, ownership lock, dividend cadence, and structure charts.

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for ABDX, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-01-15 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
2 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow live now, so the tape is framing the chart workspace below.
06:01 Today's Catalyst Appointment of NOMAD & Corporate Broker
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 129.54%
RSI Gauge
Price Change
AI Forecast